A Real-life Study of Brexpiprazole as an Adjunctive Treatment for Major Depressive Disorder in Asian Patients in Singapore (BADA)
Yee Ming Mok1, Pei Lin Lynnette Tan2, Rohini Bose3, Keira Joann Herr3, Ken Eng Khean Ung4
1Department of Mood and Anxiety, Institute of Mental Health, Singapore
2Department of Psychiatry, Tan Tock Seng Hospital, Singapore
3Medical Affairs, Lundbeck Singapore Pte Ltd, Singapore
4Adam Road Medical Centre, Singapore
Correspondence to: Rohini Bose
Medical Affairs, Lundbeck Singapore Pte Ltd, 101 Thomson Road, United Square #13-05, Singapore 307591
E-mail: ROSB@lundbeck.com
ORCID: https://orcid.org/0009-0006-6598-2369
Received: October 25, 2023; Revised: January 17, 2024; Accepted: January 18, 2024; Published online: March 12, 2024.
© The Korean College of Neuropsychopharmacology. All rights reserved.

This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Objective: To investigate the effectiveness and safety of brexpiprazole as an adjunctive treatment to antidepressant therapy (ADT) in Asian adults with major depressive disorder (MDD) and inadequate response in a real-life clinical setting in Singapore.
Methods: This was a prospective, observational 3-month study of patients with MDD who had brexpiprazole added to their existing ADT. The study was conducted at two sites in Singapore between September 2020 and October 2021. The co-primary endpoints were Patient Health Questionnaire-9 (PHQ-9) and Clinical Global Impression-Severity (CGI-S). Other endpoints included Clinical Global Impression-Improvement (CGI-I), Sheehan Disability Scale (SDS), Generalized Anxiety Disorder 7-item scale (GAD-7), and safety.
Results: Twenty patients were enrolled and 16 completed the study. There were improvements in PHQ-9, CGI-S, SDS, and GAD-7 scores from baseline at Week 12, with a mean difference of −4.8, −1.3, −8.5, and −6.2, respectively. The CGI-I score improved from baseline with a mean score of 2.3 at Week 12. One third achieved response and 25% achieved remission based on PHQ-9 scores at Week 12. Similar results were obtained using CGI-S scores (38% for both). The incidences of adverse events (AEs) and treatment-related AEs were 55% (11/20) and 50% (10/20), respectively. There were no deaths or severe AEs. Two patients withdrew brexpiprazole during the study.
Conclusion: The observed effects and safety of adjunctive brexpiprazole in Asian adults with MDD in the real-world setting in Singapore were consistent with those from clinical trials.
Keywords: Major depressive disorder; Adjunctive treatment; Antidepressants; Asian; Real world


This Article

e-submission

Archives